Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transimmunization, a novel approach for tumor immunotherapy.

Carole L Berger1, Douglas Hanlon, Daniel Kanada

  • 1Department of Dermatology, Yale University, School of Medicine, New Haven, CT 06510-8059, USA. carole.berger@yale.edu

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|July 20, 2002
PubMed
Summary

Transimmunization (TI), a novel immunotherapy, enhances extracorporeal photopheresis (ECP) by loading dendritic cells (DCs) with tumor antigens. This approach aims to improve anti-tumor immune responses for various cancers and immune disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ex vivo Sézary syndrome patient tumor cells are sensitive to ATR inhibition.

The Journal of investigative dermatology·2026
Same author

How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas.

Cancers·2026
Same author

Weekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome.

British journal of haematology·2025
Same author

Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody.

Blood·2025
Same author

Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipoidica diabeticorum.

JAAD case reports·2025
Same author

Atypical bullous systemic lupus erythematosus with features of linear IgA bullous dermatosis.

JAAD case reports·2025

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular immunology

Background:

  • Extracorporeal photopheresis (ECP) is an established immunotherapy for CTCL, autoimmune diseases, and transplant rejection.
  • Current ECP lacks optimal tumor antigen presentation for robust anti-tumor immunity.
  • Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating immune responses.

Purpose of the Study:

  • To develop a novel immunotherapy, transimmunization (TI), by modifying ECP.
  • To enhance the efficacy of DC-based immunotherapy through improved antigen loading and presentation.
  • To broaden the application of immunotherapy for various cancers and immune-related disorders.

Main Methods:

  • Modified extracorporeal photopheresis (ECP) termed transimmunization (TI).

Related Experiment Videos

  • Overnight incubation of ECP-treated cells with apoptotic tumor cells and cytokines.
  • Induction of dendritic cell (DC) differentiation and maturation.
  • Reinfusion of tumor-loaded DCs.

    • Main Results:

    • TI facilitates the transfer of tumor antigens to potent antigen-presenting cells (DCs).
    • TI promotes rapid DC differentiation and maturation from peripheral blood monocytes.
    • TI enables DCs to present a full spectrum of tumor antigens, potentially invoking anti-tumor immune responses.

    Conclusions:

    • Transimmunization (TI) is a practical and safe method for generating tumor-loaded dendritic cells (DCs).
    • TI enhances immunotherapy by optimizing antigen presentation and DC maturation.
    • This modified ECP approach holds promise for treating solid tumors and modulating immune responses in transplantation.